Merck & Co., Inc. (MRK)

82.46
0.73 0.88
NYSE
Prev Close 83.19
Open 83.25
Day Low/High 82.27 / 83.55
52 Wk Low/High 65.25 / 90.97
Volume 10.58M
Exchange NYSE
Shares Outstanding 2530.03B
Market Cap 210.95B
P/E Ratio 18.33
Div & Yield N.A. (N.A)

Latest News

How I'm Playing Astra-Zeneca on Vaccine and Acquisition News

How I'm Playing Astra-Zeneca on Vaccine and Acquisition News

I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.

November to Remember, Energy Roars, Janet Yellen, Transition, 8 Breakout Stocks

November to Remember, Energy Roars, Janet Yellen, Transition, 8 Breakout Stocks

Equity markets have run wild since Oct. 30, and it is the more economically sensitive indices that have really taken flight.

Jim Cramer: This Is All Playing Out Like a Stephen King Novel

Jim Cramer: This Is All Playing Out Like a Stephen King Novel

What happens when everyone hunkers down, creating their own de facto stay-in-place lockdown?

Jim Cramer: Health Care Stocks, the Election and the Perfect Setup

Jim Cramer: Health Care Stocks, the Election and the Perfect Setup

Right now, the market is furiously trying to price in a Blue Wave, and the health care sector is getting clobbered. But here's how I think things play out.

Red Monday, Virus Rattles Market, Political Picture, Aerospace & Defense Stocks

Red Monday, Virus Rattles Market, Political Picture, Aerospace & Defense Stocks

This is a major earnings week, electoral risk is real, the virus is already slowing velocity, and the cavalry (fiscal policy) is not coming. Sometimes, circling the wagons is not the worst idea.

Pfizer Is Trading a Lot on Hopes Ahead of Earnings

Pfizer Is Trading a Lot on Hopes Ahead of Earnings

Investors are not positioned for an upside move.

Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?

Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?

BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.

With Q3 Earnings Up Ahead, Can Johnson & Johnson Set the Table?

With Q3 Earnings Up Ahead, Can Johnson & Johnson Set the Table?

I see no reason to flee this name, therefore, I am not.

Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19

Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19

RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.

Parsing the Breakdown of FAANG

Parsing the Breakdown of FAANG

The recent market leaders appear to be running out of steam, while stalwart stocks are grinding higher, with Verizon notable among them.

Biotech M&A Picks Up: Lessons for Investors and Potential Targets

Biotech M&A Picks Up: Lessons for Investors and Potential Targets

The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.

Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff

Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff

Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.

Jim Cramer: Is This Market Undervalued?

Jim Cramer: Is This Market Undervalued?

Stocks are reasonable. Or even cheap. There will be more sell-offs ahead but remember this day and do not get too negative.

How About That Merck and Seattle Genetics Deal?

How About That Merck and Seattle Genetics Deal?

I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.

Spate of Deal News Juices Start of This Week's Trading

Spate of Deal News Juices Start of This Week's Trading

We've become accustomed lately to gap-up opens on Mondays, but some fresh acquisition agreements are helping drive this Monday's action.

This Biotech Appears to Have the Right Formula for Investors

This Biotech Appears to Have the Right Formula for Investors

After reviewing the rally, let's zero in on one biotech name, Genprex, and where it appears to be going.

The Unusual Suspects: Merck, Coca-Cola and 3M

The Unusual Suspects: Merck, Coca-Cola and 3M

Here are three names among the Dow 30 that are setting up nicely.

Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'

Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'

Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.

Jim Cramer: Betting Against Science Is a Mug's Game

Jim Cramer: Betting Against Science Is a Mug's Game

The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.

Parabolic AMD, Agreeing to Agree, Disney's GAAP Earnings Gap: Market Recon

Parabolic AMD, Agreeing to Agree, Disney's GAAP Earnings Gap: Market Recon

It is going to take successful vaccines and therapies and much lower unemployment to revive most of Walt Disney Co.'s businesses.

Jim Cramer: Clorox, Covid and Indecision on Packaged Goods Stocks

Jim Cramer: Clorox, Covid and Indecision on Packaged Goods Stocks

The whole group has run and the guidance from Clorox does show, more than anything, that nobody knows.

Grotesque GDP, So Much for Rotation, Amazon Goes Wild: Market Recon

Grotesque GDP, So Much for Rotation, Amazon Goes Wild: Market Recon

Plus, it could be quite a while before the labor market can absorb all those people who are out of jobs.

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.

Novavax and Its $1.6 Billion Award Just Got My Attention

Novavax and Its $1.6 Billion Award Just Got My Attention

The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.

I Wouldn't Buy Pfizer Shares on This Pop

I Wouldn't Buy Pfizer Shares on This Pop

I would wait until the next down day, and there will be one.

Use DRIPs to Build a Socially Responsible Portfolio

Use DRIPs to Build a Socially Responsible Portfolio

Many quality companies that fit into the socially responsible investing camp offer direct-purchase plans, allowing investors an easy way to build an SRI portfolio.

Check Out These 2 Undervalued Drugmakers

Check Out These 2 Undervalued Drugmakers

I plan to add some additional exposure to each on the next 'hiccup' in the market using my usual covered call strategy.

Jim Cramer: Are You a Star Player? Let's Put It to the Test

Jim Cramer: Are You a Star Player? Let's Put It to the Test

Do you know what a company does, does it do it well, and is there anything going on that could change the trajectory?